Clinical trial · Interventional
Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors
Phase 2 Study Evaluating the Efficacy of Epoetin Beta (Neocormon®) For Fatigue and Quality of Life of Patients Receiving Palliative Care for a Solid Malignant Tumor
NCT00559195CI-TRIAL-00004834completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Epoetin beta may cause the body to make more red blood cells and may help relieve fatigue in patients with malignant solid tumors receiving palliative care. PURPOSE: This phase II trial is studying how well epoetin beta works in treating fatigue and anemia in patients receiving palliative care for malignant solid tumors.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Fatigue | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| epoetin beta | Biological | — | UNRESOLVED |
| quality-of-life assessment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Fatigue
- measure
- Quality of life
Secondary outcomes (1)
- measure
- Hemoglobin level
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed malignant solid tumor * No hematologic malignancy * Hemoglobin \< 10.5 g/dL (anemic) * Receiving palliative care only PATIENT CHARACTERISTICS: * Life expectancy \> 6 months * Negative pregnancy test * Fertile patients must use effective contraception * No chronic anemia requiring treatment (e.g., thalassemia or sickle cell disease) * No uncontrolled hypertension * No allergy to any drugs or components used in the study * Not a prisoner or under guardianship or trusteeship * No mental disability that impairs a clear understanding of the study requirements PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 2 months since prior specific anticancer therapy (e.g., chemotherapy, hormonal therapy, targeted therapy, or immunotherapy) * More than 1 month since prior and no concurrent participation in another clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.